Sort
40,608 grants matching “prostate cancer”
NEUROPILIN-2 INHIBITOR AS A POTENT THERAPY FOR PROSTATE CANCER BONE METASTASIS.
$766,117Virginia Commonwealth University · · FY2021 · Defense Health Agency
MOLECULAR APPROACHES TO DISCOVER MARINE NATURAL PRODUCT
$765,921University Of California Santa Cruz · U19 · FY2001 · CA
Leveraging whole-exome sequence data from diverse biobanks and cohorts to study rare coding variation in prostate cancer
$765,904Christopher Alan Haiman · University Of Southern California · R01 · FY2023 · CA
Epigenetic Regulation of Normal and Pathologic CTCF Functions by BORIS
$765,771Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
IMPLICATIONS OF MENTAL HEALTH ILLNESS ON OUTCOMES OF PROSTATE CANCER PATIENTS IN THE VETERANS AFFAIRS MEDICAL SYSTEM.
$765,615Augusta University Research Institute, Inc · · FY2020 · Defense Health Agency
Iowa Oncology Research Association
$765,544Robert J. Behrens · Iowa Oncology Research Association · U10 · FY2008 · CA
Biological Functions of Chromosomal Proteins
$765,529Michael Bustin · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Clinical Qualification of Imaging and Fluid-Based Tumor Monitoring Biomarkers for Metastatic Castration Resistant Prostate Cancer
$765,415Lawrence H Schwartz · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Integrative Molecular Epidemiology of Human Cancer
$765,170Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
HIGH-THROUGHPUT SCREEN OF ADVANCED PROSTATE CANCER ORGANOIDS AND PDX PRECLINICAL TRIALS TO IDENTIFY SINGLE AND COMBINATION THERAPIES CORRELATED WITH
$765,046The Geneva Foundation · · FY2018 · Department of the Army
The VITamin D and OmegA-3 TriaL (VITAL): Post-Intervention Follow-Up
$765,000Joann Elisabeth Manson · Brigham And Women'S Hospital · R01 · FY2025 · AT
Randomized trial of community health worker-led decision coaching to promote shared decision making for prostate cancer screening among Black male patients and their providers
$764,825Danil V. Makarov · New York University School Of Medicine · R01 · FY2021 · MD
SurvivorCare: A digital health solution to support long-term cancer survivorship using patient navigation
$764,805Y. Xian Ho · Dimagi, Inc. · R44 · FY2021 · CA
Circulating metabolites as novel risk biomarkers for gastric cancer: a large multi-center prospective investigation
$764,565Xiang Shu · Sloan-Kettering Inst Can Research · R37 · FY2024 · CA
Mechanisms of pathogenesis in patient derived organoid models of prostate cancer
$764,220Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
COMBINING NANOTECHNOLOGY AND RADIATION TO ENHANCE CHECKPOINT BLOCKADE IMMUNOTHERAPY OF ADVANCED PROSTATE CANCER
$764,202University Of Chicago · · FY2018 · Department of the Army
GENETIC VARIATIONS IN SLCO TRANSPORTER GENES CONTRIBUTING TO RACIAL DISPARITY IN AGGRESSIVENESS OF PROSTATE CANCER
$764,100Health Research, Inc. · · FY2014 · Department of the Army
Missouri Valley Cancer Consortium CCOP
$763,999Missouri Valley Cancer Consortium, Inc. · U10 · FY2003 · CA
conjugation of constrained peptides for cancer diagnostics
$763,704Ingrid Schroeder · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
COMBINED TARGETING OF ANTIGENS EXPRESSED ON PROSTATE CANCER & PROSTATE STEM CELLS USING LISTERIA-BASED CANCER VACCINES FOR TREATMENT OF PROSTATE CANC
$763,592Aduro Biotech · · FY2012 · Department of the Army
Nutiritional and Biochemical/Genetic Markers of Cancer
$763,583Brigham And Women'S Hospital · R01 · FY2003 · CA
Development of Drugs Acting at Adenosine Receptors
$763,518Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2020 · DK
Early Detection Research Network (EDRN) BiomarkerReferenceResourceCenter (BRRC)
$763,499National Cancer Institute · Y01 · FY2012 · CA
Inhibitors of protein-protein interactions
$763,200Nadya Tarasova · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
CENTER FOR BIOMEDICAL RESEARCH
$763,121Clayton Yates · Tuskegee University · G12 · FY2014 · MD